Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXGNNASDAQ:NVCRNASDAQ:SSIINYSE:WRBY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXGNAxoGen$11.83+0.4%$16.13$5.74▼$21.00$538.68M1.19461,720 shs503,244 shsNVCRNovoCure$17.89+1.7%$17.70$14.17▼$34.13$1.99B0.731.16 million shs725,408 shsSSIISS Innovations International$9.84-1.1%$0.00$0.32▼$22.42$1.90BN/A22,745 shs14,659 shsWRBYWarby Parker$17.71+0.8%$16.96$12.46▼$28.68$1.85B2.011.81 million shs2.01 million shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXGNAxoGen-0.34%-6.74%-24.73%-35.02%+97.98%NVCRNovoCure+2.87%+0.78%+6.87%-21.75%-16.44%SSIISS Innovations International-1.00%+994,999,900.00%+994,999,900.00%+994,999,900.00%+994,999,900.00%WRBYWarby Parker+0.86%+5.80%+18.90%-31.60%+11.90%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAXGNAxoGen3.4346 of 5 stars3.55.00.00.03.02.50.6NVCRNovoCure3.6672 of 5 stars3.31.00.04.53.41.70.0SSIISS Innovations InternationalN/AN/AN/AN/AN/AN/AN/AN/AWRBYWarby Parker3.7059 of 5 stars4.33.00.00.02.04.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXGNAxoGen 3.00Buy$22.2087.66% UpsideNVCRNovoCure 2.67Moderate Buy$32.8383.53% UpsideSSIISS Innovations International 0.00N/AN/AN/AWRBYWarby Parker 2.69Moderate Buy$22.0024.23% UpsideCurrent Analyst Ratings BreakdownLatest AXGN, NVCR, WRBY, and SSII Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025AXGNAxoGenCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$26.00 ➝ $24.005/13/2025WRBYWarby ParkerUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$23.00 ➝ $20.005/9/2025WRBYWarby ParkerThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $20.005/9/2025WRBYWarby ParkerTelsey Advisory GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$30.00 ➝ $22.005/1/2025WRBYWarby ParkerTelsey Advisory GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$30.00 ➝ $30.004/30/2025WRBYWarby ParkerCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSell ➝ Neutral$23.00 ➝ $17.004/23/2025NVCRNovoCurePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$42.00 ➝ $34.004/22/2025WRBYWarby ParkerThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$29.00 ➝ $18.004/17/2025WRBYWarby ParkerLoop CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$27.004/16/2025NVCRNovoCureWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$29.00 ➝ $27.004/14/2025WRBYWarby ParkerJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$30.00 ➝ $22.00(Data available from 5/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXGNAxoGen$187.34M2.88N/AN/A$2.22 per share5.33NVCRNovoCure$621.71M3.21N/AN/A$3.39 per share5.28SSIISS Innovations International$20.65M92.24N/AN/AN/A∞WRBYWarby Parker$795.09M2.33N/AN/A$3.08 per share5.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXGNAxoGen-$21.72M-$0.15N/AN/AN/A-7.91%-14.91%-7.49%N/ANVCRNovoCure-$207.04M-$1.51N/AN/AN/A-25.93%-41.48%-12.74%7/24/2025 (Estimated)SSIISS Innovations InternationalN/AN/A0.00∞N/AN/AN/AN/AN/AWRBYWarby Parker-$63.20M-$0.12N/A177.09N/A-4.39%-8.26%-4.37%N/ALatest AXGN, NVCR, WRBY, and SSII EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/24/2025Q1 2025NVCRNovoCure-$0.47-$0.31+$0.16-$0.31$147.57 million$154.99 million2/27/2025Q4 2024NVCRNovoCure-$0.34-$0.61-$0.27-$0.61$161.30 million$161.27 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXGNAxoGenN/AN/AN/AN/AN/ANVCRNovoCureN/AN/AN/AN/AN/ASSIISS Innovations InternationalN/AN/AN/AN/AN/AWRBYWarby ParkerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXGNAxoGen0.673.742.47NVCRNovoCure0.271.491.44SSIISS Innovations InternationalN/AN/AN/AWRBYWarby ParkerN/A2.472.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXGNAxoGen80.29%NVCRNovoCure84.61%SSIISS Innovations InternationalN/AWRBYWarby Parker93.24%Insider OwnershipCompanyInsider OwnershipAXGNAxoGen7.00%NVCRNovoCure6.29%SSIISS Innovations InternationalN/AWRBYWarby Parker26.55%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXGNAxoGen45045.54 million40.93 millionOptionableNVCRNovoCure1,320111.49 million101.40 millionOptionableSSIISS Innovations International4193.56 millionN/AN/AWRBYWarby Parker3,030104.50 million74.67 millionOptionableAXGN, NVCR, WRBY, and SSII HeadlinesRecent News About These CompaniesWarby Parker (NYSE:WRBY) Price Target Cut to $20.00 by Analysts at UBS GroupMay 16 at 3:59 AM | americanbankingnews.comNorthern Trust Corp Acquires 56,674 Shares of Warby Parker Inc. (NYSE:WRBY)May 16 at 3:46 AM | marketbeat.comWhich Is a Better Investment, The Buckle, Inc. or Warby Parker Inc. Stock?May 15 at 10:41 AM | aaii.comWhat Warby Parker’s Co-Founder Can Teach You About Breaking Into a Crowded IndustryMay 15 at 10:41 AM | inc.comBNP Paribas Financial Markets Buys Shares of 295,693 Warby Parker Inc. (NYSE:WRBY)May 15 at 4:01 AM | marketbeat.comWarby Parker (NYSE:WRBY) Shares Gap Up Following Analyst UpgradeMay 14 at 10:50 AM | marketbeat.comInvenomic Capital Management LP Sells 218,931 Shares of Warby Parker Inc. (NYSE:WRBY)May 14 at 6:08 AM | marketbeat.comAre Options Traders Betting on a Big Move in Warby Parker (WRBY) Stock?May 13 at 8:26 PM | msn.comD. E. Shaw & Co. Inc. Purchases 199,235 Shares of Warby Parker Inc. (NYSE:WRBY)May 13 at 6:02 AM | marketbeat.comWarby Parker (NYSE:WRBY) Shares Gap Up After Analyst UpgradeMay 13 at 1:13 AM | americanbankingnews.comTelsey Advisory Group Cuts Warby Parker (NYSE:WRBY) Price Target to $22.00May 12, 2025 | americanbankingnews.comHow some early feedback put Warby Parker on the path to successMay 11, 2025 | msn.comWarby Parker (NYSE:WRBY) Price Target Cut to $22.00 by Analysts at Telsey Advisory GroupMay 11, 2025 | marketbeat.comDriehaus Capital Management LLC Grows Stake in Warby Parker Inc. (NYSE:WRBY)May 11, 2025 | marketbeat.comAlgert Global LLC Reduces Stake in Warby Parker Inc. (NYSE:WRBY)May 11, 2025 | marketbeat.comWarby Parker (NYSE:WRBY) Price Target Raised to $20.00 at The Goldman Sachs GroupMay 11, 2025 | americanbankingnews.comWarby Parker Inc. (WRBY) Q1 2025 Earnings Call TranscriptMay 10, 2025 | seekingalpha.comEarnings call transcript: Warby Parker Q1 2025 results reveal revenue growthMay 10, 2025 | uk.investing.comWarby Parker Inc. (WRBY): Among Nicholas J. Pritzker’s Stock Picks with Huge Upside PotentialMay 10, 2025 | finance.yahoo.comWarby Parker Inc (WRBY) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...May 9, 2025 | finance.yahoo.comDurable Capital Partners LP Has $218.32 Million Holdings in Warby Parker Inc. (NYSE:WRBY)May 9, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAXGN, NVCR, WRBY, and SSII Company DescriptionsAxoGen NASDAQ:AXGN$11.83 +0.05 (+0.42%) Closing price 04:00 PM EasternExtended Trading$11.57 -0.26 (-2.20%) As of 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.NovoCure NASDAQ:NVCR$17.89 +0.30 (+1.71%) Closing price 04:00 PM EasternExtended Trading$17.89 0.00 (0.00%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.SS Innovations International NASDAQ:SSII$9.84 -0.11 (-1.11%) As of 04:00 PM EasternAVRA Medical Robotics, Inc. develops and manufactures medical surgical devices. The company has a research agreement with the University of Central Florida to develop navigation and control technologies with applications in medical robotics. The company was formerly known as AVRA Surgical Microsystems, Inc. and changed its name to AVRA Medical Robotics, Inc. in November 2015. AVRA Medical Robotics, Inc. was founded in 2015 and is based in Orlando, Florida.Warby Parker NYSE:WRBY$17.71 +0.14 (+0.79%) Closing price 03:59 PM EasternExtended Trading$17.58 -0.13 (-0.73%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Warby Parker Inc. provides eyewear products in the United States and Canada. The company offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, non-prescription lenses, and contact lenses. It also provides accessories, such as cases, lenses kit with anti-fog spray, pouches, and anti-fog lens spray through its retail stores, website, and mobile apps. In addition, the company offers eye exams and vision tests. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades An Acquisition Just Made Dick's the Most Exciting Stock in Retail CRSPR Stock Could Be Ready to Deliver on Its Massive Promise Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
